Government Report: IAVT Research Team and Reber Genetics Co., Ltd Unveil Next-generation Vaccine to Eradicate Porcine Epidemic Diarrhea Virus
According to a recent report published on Taiwan’s Government Research Bulletin (GRB), veterinary researchers have achieved a crucial milestone in safeguarding the agricultural sector. The official release highlights the successful development of a next-generation vaccine designed to combat the devastating Porcine Epidemic Diarrhea Virus (PEDV), a major threat to the global swine industry.
The National Agricultural Threat
The government dispatch notes that since a highly lethal PEDV variant emerged in Taiwan in late 2013, the virus has caused catastrophic agricultural losses. While harmless to humans, the virus causes severe dehydration and diarrhea in pigs. With a mortality rate approaching 100% in piglets under seven days old, the disease has historically claimed over 400,000 piglets annually, severely disrupting the swine supply chain and destabilizing pork prices.
A Collaborative Breakthrough
To resolve this crisis, the report details a three-year research initiative led by a team from the IAVT department of the National Pingtung University of Science and Technology (NPUST)—including Distinguished Professor Chu Chun-Yen, Associate Professor Wu Hsing-Chieh, and Assistant Professor Doan Thi Thu Dung—in collaboration with Reber Genetics Co., Ltd. Together, they successfully developed the Next-Generation Porcine Coronavirus Vaccine.
Key Innovations Highlighted in the Official Report:
Dual-Delivery Immunization: The vaccine utilizes a comprehensive approach. Intramuscular injections stimulate IgG antibodies for systemic immunity, while oral administration induces IgA antibodies, triggering a strong mucosal immune response in sows.
Maternal Antibody Protection: Rather than directly vaccinating fragile newborns, the strategy ensures sows pass robust maternal antibodies (MA) to their piglets through colostrum. This provides immediate, life-saving protection to piglets right after birth.
Cost-Effective Application: Official field trials confirm that the vaccine is highly efficient and offers an excellent cost-to-performance ratio for pig farmers, significantly lowering both infection and mortality rates through indirect protection.
Official Recognition and Global Outlook
The GRB publication confirms that this precision-engineered vaccine—which includes both subunit and DNA formats—earned the prestigious 2024 NSTC Future Tech Award. Furthermore, the government notes that the research team has successfully secured invention patents in Taiwan and China, and the technology has been transferred to industry partners for mass production. Officials emphasize that this innovative vaccine platform will not only protect domestic swine populations but also elevate Taiwan’s biotechnology manufacturing capabilities, paving the way for future vaccines against other animal and zoonotic diseases on the global stage.
Official Source: Taiwan Government Research Bulletin (GRB) – Report 19098528
